February 4, 2021

The Honorable Xavier Becerra
Secretary Designee
Department of Health and Human Services
Hubert H. Humphrey Building
200 Independence Avenue, SW
Washington, D.C.  20201

Re:    CMMI Part D Payment Modernization Models

Dear Secretary Designee Becerra:

The undersigned organizations represent millions of patients and consumers facing serious and chronic health conditions. We write in response to the new flexibilities for calendar year (CY) 2022 offered to Part D sponsors who participate in the Medicare Part D Payment Modernization models that were announced under the previous administration by the Center for Medicare & Medicaid Innovation (CMMI) on January 19, 2021. We believe the two new options – allowing for flexibility with respect to the six protected classes and allowing Part D plan sponsors to limit drug coverage to at least one drug per class – could jeopardize beneficiary access to medically necessary prescription drugs and harm patients with serious illness such as cancer, HIV/AIDS, epilepsy, mental health issues, and transplant patients. We strongly urge the current Administration to not move forward with these two new flexibilities and rescind the policy.

Six Protected Classes Flexibilities

The proposed policy change to the demonstration made by the former administration would permit Part D sponsors approved for participation to treat five of the six protected classes – anticonvulsants, immunosuppressants, antidepressants, antipsychotics, and antineoplastics) as they would any other Part D drug. For CY 2023 Part D sponsors participating in the Model would be permitted to treat antiretrovirals, the remaining protected class, as they would any other Part D drug. In other words, Part D plans that are approved for participation in this model would no longer have to cover “all or substantially all” drugs within these classes.

The creation of this new flexibility contradicts the intent of the Part D program, and the six protected classes. As noted in the Part D manual the protected classes policy exists “because it was necessary to ensure that Medicare beneficiaries reliant upon these drugs would not be substantially discouraged from enrolling in certain Part D plans, as well as to mitigate the risks and complications associated with an interruption of therapy for these vulnerable populations.” Beneficiaries who rely on these drug therapies often have co-morbidities that could be negatively impacted by any potential change.

2 Centers for Medicare & Medicaid Services, Medicare Prescription Drug Benefit Manual, Ch. 6 – Part D Drugs and Formulary Requirements, sect. 30.2.5.
The proposed policy change suggests this flexibility is necessary in order to give Part D sponsors greater ability to negotiate with manufacturers. However, this justification fails to take into account that Part D plans already have more restrictive formularies for drugs covered under the six protected classes relative to commercial plans, which suggest that the current policy does not prevent Part D Plan sponsors from effectively managing formularies within these drug classes. Part D generic utilization is high among drug classes within the six protected classes, with generic utilization for drugs within the six protected classes being higher than other drug classes (92 percent versus 84 percent).

**One Drug Per Class Flexibility**

The former administration’s proposal also offers an additional flexibility that would allow Part D sponsors to include on their formulary at least one drug per class, rather than the statutory requirement of at least two drugs per class. It is not clear from the information provided whether Part D sponsors would be able to meet this requirement by covering only a generic drug (if one exists) or whether the sponsor would be required to cover a branded drug.

We are deeply concerned this policy would limit Medicare beneficiaries’ access to medically appropriate therapies. Part D sponsors already have a number of tools at their disposal to encourage beneficiaries to utilize lower-cost alternatives. They can create a formulary and exclude certain drugs from coverage, they can tier drugs to encourage the use of lower-cost alternatives, and they can impose utilization management edits on medications. These tools have been in place since the Part D program was first implemented in 2006 and the proposed policy change offers no justification as to why such a drastic change is needed at this time.

**Beneficiary Protections Are Insufficient**

The CMMI fact sheet notes that while the proposal intends to waive the six protected classes requirements and the one drug per class requirement, all other beneficiary protections would remain in place and provide sufficient protection to ensure beneficiaries have access to Part D drugs. We strongly disagree.

*One or both flexibilities would jeopardize beneficiary access*: We are concerned that both policies to provide additional flexibilities would result in fewer covered Part D drugs for beneficiaries. This is a particularly serious problem for beneficiaries with serious chronic conditions who rely on specific medication therapies to treat their conditions. Beneficiaries who are not able to be stabilized on outpatient prescription drugs are more likely to require additional medical care which would increase health care expenditures under the Medicare Part A and B programs, not only costing the beneficiary

---


additional time and a decreased quality of life, but also needlessly increasing overall Medicare expenditures. We are also concerned that the limited information provided in the proposal would allow a Part D sponsor to seek approval for both the six protected classes and the one drug per class flexibilities.

**Part D appeals process provides an insufficient safeguard:** While the proposal intends to retain the current Part D appeals process, we are concerned that the existing appeals process is confusing and complex and in need of improvements. The Medicare Payment Advisory Commission has noted the appeals process can be time consuming, frustrating, and burdensome for some beneficiaries.

The policies under consideration will likely result in a significant increase in the number of appeals and exceptions, which can further burden the existing process. This is particularly concerning given that in announcing the flexibilities the proposal does not address any additional CMS resources (such as additional staff or appropriations) to ensure that beneficiaries who need access to drugs within the protected classes are able to obtain their medications in a timely manner.

**Part D transition supply policy provides insufficient safeguard:** The proposal suggests that Part D sponsors who have been approved to implement the formulary flexibilities (e.g., the six protected classes flexibility) will be required to provide an enhanced transition process for drugs in the protected classes, including both proactive outreach to current enrollees and an extended transition supply that provides for “multiple” temporary fills. While we appreciate that the proposal attempts to mitigate the damage caused to beneficiaries by its six protected class flexibility, we do not believe this extended transition policy is sufficient. The transition supply would provide for temporary fills within the first 120 days of the calendar year. It is unclear whether all Part D sponsors approved to participate in the six protected classes flexibility model would be subject to the same number of temporary fills, and whether CMMI or the Part D sponsor determines the appropriate number of fills.

**Conclusion**

Given the potential harm to the populations we serve, we urge the Department to not move forward with either of these new flexibilities and rescind the proposed policy change by the previous administration. These changes could result in cost-shifting to beneficiaries and could jeopardize vulnerable beneficiaries’ access to medically necessary prescription drugs for patients with serious illness such as cancer, HIV/AIDS, epilepsy, mental health issues, and transplant patients.

Thank you for the opportunity to provide feedback on these proposed policy changes put forward during the last days of the prior administration. We would welcome the opportunity to meet with you to discuss our concerns in more detail. If you have any questions or would like to discuss our comments further, please contact Keysha Brooks-Coley, VP Federal Advocacy and Strategic Alliances, American Cancer Society Cancer Action Network at Keysha.brooks-coley@cancer.org or 202-661-5720.

Sincerely,

---


9 CMMI Fact Sheet at 2.
American Cancer Society Cancer Action Network
Alliance for Aging Research
ADAP Advocacy Association
Alliance for Patient Access
American Autoimmune Related Diseases Association
American Brain Coalition
American Kidney Fund
American Liver Foundation
American Lung Association
American Psychiatric Association
American Society of Consultant Pharmacists
Association for Clinical Oncology
Association of Community Cancer Centers (ACCC)
Association of Oncology Social Work
Be The Match/National Marrow Donor Program
Cancer Support Community
CancerCare
Children's Cancer Cause
College of Psychiatric and Neurologic Pharmacists
Colorectal Cancer Alliance
Community Access National Network (CANN)
Depression and Bipolar Support Alliance
Epilepsy Foundation
Fight Colorectal Cancer
FORCE: Facing Our Risk of Cancer Empowered
Global Liver Institute
GO2 Foundation for Lung Cancer
HealthHIV
Hematology/Oncology Pharmacy Association
Hemophilia Federation of America
HIV + Hepatitis Policy Institute
Hope for ULD
International Myeloma Foundation
KidneyCAN
Livestrong
LUNGevity Foundation
Lupus and Allied Diseases Association, Inc.
Lupus Foundation of America
Lymphoma Research Foundation
Melanoma Research Foundation
Men's Health Network
Metastatic Breast Cancer Network
METAvivor
National Alliance on Mental Illness
National Association of Chronic Disease Directors
National Association of Epilepsy Centers
National Brain Tumor Society
National Cancer Registrars Association
National Coalition for LGBT Health
National Comprehensive Cancer Network
National Council for Behavioral Health
National Health Council
National Hemophilia Foundation
National Kidney Foundation
National Organization for Rare Disorders
National Pancreas Foundation
National Patient Advocate Foundation
Oncology Nursing Society
Ovarian Cancer Research Alliance
Phelan-McDermid Syndrome Foundation
Prevent Cancer Foundation
Ring14 USA
Sarcoma Foundation of America
Schizophrenia and Related Disorders Alliance of America
Susan G. Komen
The AIDS Institute
The Kennedy Forum
The Leukemia & Lymphoma Society
The NORSE Institute
Transplant Recipients International Organization
Transplant Support Organization
Triage Cancer
Tuberous Sclerosis Alliance
Wishes for Elliott/DEE-P Connections
ZERO - The End of Prostate Cancer